/DISREGARD RELEASE: Celltrion/
- Written by PR Newswire
We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire.
Read more https://www.prnasia.com/story/archive/4693107_CN93107_0